Video Experimental Relacionado
Updated: Aug 14, 2026
07:59
Spectrophotometric Methods for the Study of Eukaryotic Glycogen Metabolism
Published on: August 19, 2021
Las mutaciones en el gen de la glucosa-6-fosfatasa que causan la enfermedad de almacenamiento de glucógeno tipo 1aa
1Human Genetics Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892.
Science (New York, N.Y.)
|October 22, 1993
Resumen
La enfermedad del almacenamiento de glucógeno tipo 1a es el resultado de una deficiencia de D-glucosa-6-fosfatasa (G6Pase). Los investigadores identificaron mutaciones genéticas específicas que causan esta deficiencia de enzimas, revelando la base molecular de la enfermedad.
Área de la Ciencia:
- La bioquímica es la bioquímica.
- Genética La genética.
- Biología Molecular Biología Molecular
Sus antecedentes:
- La enfermedad del almacenamiento de glucógeno (GSD) tipo 1a es un trastorno metabólico.
- Se deriva de una deficiencia de la enzima D-glucosa-6-fosfatasa (G6Pase).
- Los mecanismos moleculares detrás del GSD tipo 1a no se han comprendido completamente.
Objetivo del estudio:
- Para realizar la caracterización molecular y bioquímica de la G6Pase humana.
- Para identificar la base genética del GSD tipo 1a.
Principales métodos:
- Caracterización molecular del ADN y el gen complementario de la G6Pasa humana.
- Análisis bioquímico de la proteína G6Pasa expresada.
- Análisis de mutación en el gen G6Pase de individuos afectados.
Principales resultados:
- Se caracterizó el gen humano G6Pase y su proteína expresada.
- Se encontró que la proteína expresada era indistinguible de la G6Pase. microsomal humana.
- Se identificaron varias mutaciones en el gen G6Pase en pacientes, lo que condujo a una inactivación completa de la enzima.
Conclusiones:
- El estudio establece la base molecular de la enfermedad del almacenamiento de glucógeno tipo 1a.
- Las mutaciones identificadas proporcionan una base para comprender la enfermedad.
- Estos hallazgos allanan el camino para posibles futuras estrategias de terapia génica.
Más Videos Relacionados
Videos de Conceptos Relacionados
01:22Lysosomal Hydrolases
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
01:27Glucose Transporters
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
01:20Inborn Errors of Metabolism
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
01:12Type I Diabetes I: Introduction
Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
01:26Type I Diabetes II: Pathophysiology
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.